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IsatinAbstract New series of oxindol-based heterocyclic entities (2–11) have been designed and synthe-
sized using indolin-2-one derivatives as key materials (1a–d). The chemical structures of the new
synthesized compounds were characterized by FTIR, 1HNMR, 13CNMR, MS spectroscopy and
elemental analyses. Three of the newly synthesized compounds were tested for anticancer activity
in the National Cancer Institute (NCI) against human panel breast cancer cell line MCF7, from
the in vitro assays compound 6c presented promising anti-cancer activity using Doxorubicin as a
reference. Compound 6c could be a lead compound for discovery of new anticancer agent.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Medicinal chemistry concerns with the discovery, develop-
ment, interpretation and the identiﬁcation of mechanism of
action of biologically active compounds at the molecular level.
Various biologically active synthetic compounds have
ﬁve-membered nitrogen-containing heterocyclic ring in their
structures. An important aspect of medicinal chemistry has
been to establish a relationship between chemical structure
and pharmacological activity (Delgado et al., 1998). It has
been established that half of the therapeutic agents consists
of heterocyclic compounds. The heterocyclic ring comprises
of very core of the active moiety or the pharmacophore (Millerand Remington, 1995). In recent years multicomponent reac-
tions (MCR’s) (Domling, 2006; Cariou et al., 2008, Umkeherer
et al., 2006; Alizadeh et al., 2006; Domling et al., 2000) leading
to interesting heterocyclic scaffolds have emerged as powerful
tools for incorporating the molecular diversity needed in com-
binatorial approaches for the synthesis of bioactive com-
pounds and producing diverse chemical libraries of drug-like
compounds for biological screening (Weber, 2002, Drug Disc.
Today). Indolin-2-one and its derivatives have been designed
as a novel class of tyrosine kinase inhibitors, which exhibit
selectivity towards different receptor tyrosine kinases (RTK’s]
(Sun et al., 1998; Lackey et al., 2000; Cho et al., 2010; Kiefer
et al., 2010; Mologni et al., 2010).
Various indolin-2-ones have been identiﬁed as pharmacolog-
ically active compounds in extracts of the traditional
anti-inﬂammatory herb Isatis tinctoria. Furthermore; it has been
shown that they inhibit compound 48/80-induced mast cell
degranulation in vitro. Since indolinone systems are useful and
important in the ﬁeld of medicinal chemistry, the development
of simple, convenient, and high-yielding protocols is desirable.
Efﬁcient synthesis of new oxindol-based heterocyclic entities via indolin-2-one derivatives 631The indolin-2-one ring system belongs to the privileged
structure in modern medicinal chemistry, particularly in the
discovery of new antitumor and anti-angiogenic agents.
Indolin-2-one derivatives, especially those with heterocyclic
methylene substituents attached to the C-3 position of the
indolin-2-one ring, have been disclosed as potent inhibitors
of RTK in vitro and demonstrated anti-angiogenic properties
in vivo. The 3-[(3, 5-dimethyl-1H-pyrrol-2-yl) methylene] indo-
lin-2-one structure is found in many antitumor drugs (Lv et al.,
2011; Uddin et al., 2010). Also it was reported that indolin-2-
ones in Clinical Trials act as Potential Kinase Inhibitors
(Chinnasamy et al., 2012). Cancer is one of the global health
problems and the most frightening and fatal disease of human
(Demirayak et al., 2011). Development and discovery of new
anticancer agents are one of the main goals in medicinal chem-
istry. A variety of 3-substituted indolin-2-ones have been uti-
lized as anticancer drugs or drug candidates as shown in
Fig. 1 (Krug and Hilgeroth, 2008; Underiner et al., 2004;
Chow and Gail Eckhardt 2007; Sandrine et al., 2007; Kumar
et al., 2013).The indolin-2-one based Sunitinib is a small-mol-
ecule inhibitor of multiple RTK involved in cancer, including
VEGFR and PDGFR. It was approved by the USFDA for
the treatment of GIST and advanced renal-cell carcinoma in
January 2006 and European Union approval in January
2007. Sunitinib is the ﬁrst anti-cancer drug which received
simultaneous FDA approval for two different indications. It
has potent anti-angiogenic effects and direct antitumor activi-
ties due to the selective inhibition of VEGFR-1 (also known as
FLT1), VEGFR-2 (also known as FLK1/KDR), VEGFR3
(also known as FLT4), PDGFRa, PDGFRb, c-kit, FLT3,
RET, and CSF1R (Sandrine et al., 2007; Chow and Gail,
2007).
In continuation of our studies in the synthesis of novel
biologically important heterocyclic compounds incorporated
with oxindole moiety (El Abbady et al., 1974; Kandile et al.,
1991a,b; Hamad et al., 2003; Elgazwy et al., 2006; Zaky
2006, 2007; Kandile et al., 2012,2013), we herein report
efﬁcient methods for the synthesis of new oxindol-based
heterocyclic entities’ derivatives using indolin-2-one derivatives
as key materials.
2. Materials and methods
2.1. General
All melting points are uncorrected and were determined on a
Gallenkamp melting point apparatus Model MFB 595-0366.
Infrared spectra were measured on a Perkin–Elmer spectro-
photometer model 1430 using potassium bromide pellets andFigure 1 Structures of indfrequencies are reported in cm1. The 1H NMR and 13C
NMR were measured in DMSO-d6 on a Varian Genini-
300 MHz spectrometer and chemical shifts d are in ppm. The
mass spectra (m/z) values were measured on a mass spectro-
photometer HP model GC MS-QPL000EX (Shimadzu) at
70 eV. Elemental analyses were carried out at the Microanalyt-
ical Centre, Cairo University. Explorer Automated Microwave
Synthesis Workstation (CEM) was used for the synthesis of
compounds.2.2. Chemistry
2.2.1. Synthesis of 3-[2-oxo-5-(2-methoxyphenyl) furan-
3(2H)-ylidene] indolin-2-one (1b)
Furanone derivative was prepared via condensation of ﬁnely
powdered b-(2-methoxybenzoyl) propionic acid (0.01 mol),
fused sodium acetate (0.01 mol) and isatin (0.01 mol) in acetic
anhydride (10 ml) via microwave irradiation at 200 C for
2 min. The reaction mixture was cooled, ﬁltered off and the
precipitate was washed with water and petroleum ether (b.p.
40–60 C). The solid product was crystallized from acetic acid
to give (1b).
2.2.2. 3-[2-Oxo-5-(2-methoxyphenyl) furan-3(2H)-ylidene]
indolin-2-one 1b
Dark brown solid, yield 77%; mp 120 C; IR: 3315 for (NH),
1699 for (C‚Olactone) 1680-1645 for (C‚Oamide) cm
1. 1H
NMR: d 10.00 (s, 1H, NH), 7.85-6.99 (m, 8H, 2Ar-H), 6.89
(s, 1H, CH), 3.25 (s, 3H, CH3 of CH3O-Ar) ppm,
13C NMR
d: 170.3, 167.4, 159.9, 146.2, 146.1, 144.0, 136.3, 128.2, 127.4,
126.6, 124.3, 122.7, 121.5, 114.2, 99.2, 55.9. Anal.
C19H13NO4 (319.304): Calcd: C, 71.46; H, 4.10; N, 4.39;
Found: C, 71.53; H, 3.99; N, 4.53. Ms: m/z 319 M+.
2.2.3. Synthesis of 1-[4-(1-acetyl-2-oxoindolin-3-ylidene)-5-
oxo-2-phenyl-4,5-dihydro-imidazol-1-yl] thiourea 2
A mixture of (1d) (0.01 mol) and thiosemicarbazide (0.01 mol)
in absolute ethyl alcohol (30 ml) was heated under reﬂux for
3 h. The reaction mixture after cooling was poured upon cold
water. The solid that separated was ﬁltered off and crystallized
from benzene to give (2).
Dark red solid, yield 55%; mp 205-7 C; IR: 3285 for (NH),
3183 for (NH of NH2), 1690-1675 for (C‚O), 1606 for (C‚N)
cm1. 1H NMR: d 10.40 (s, 1H, NH), 9.6 (s, 2H, NH2), 7.52-
7.28 (m, 9H, 2Ar-H) and 3.07 (s, 3H, CH3 of COCH3) ppm,
Anal. C20H15N5O3S (405.37): Calcd: C, 59.25; H, 3.73; N,
17.28, S, 7.89 Found: C, 59.02; H, 3.87; N, 16.98; S, 8.12.
Ms: m/z 405 M+.olin-2-one derivatives.
632 H.T. Zaky et al.2.2.4. Synthesis of 1-acetyl-3-(5-phenyl-2-thioxo-2,3-
dihydroimidazo [1,5-b][1,2,4]-triazol-7-ylidene) indolin-2-one 3
Method A:
A solution of (1d) (0.01 mol) and thiosemicarbazide
(0.01 mol) in glacial acetic acid (30 ml) was heated under reﬂux
for 2 h. The reaction mixture after cooling was poured upon
cold water. The solid product formed was ﬁltered off and crys-
tallized from ethyl alcohol to give (3).
Method B:
Heat (2) (0.01 mol) in glacial acetic acid (30 ml) for 2 h. The
reaction mixture after cooling was poured upon cold water.
The solid product formed was ﬁltered off and crystallized from
ethyl alcohol to give (3).
Dark violet solid, yield 65%; mp 188-90 C; IR: 3202 for
(NH), 1666-1621 for (C‚O) cm1. 1H NMR: d 10.82 (s, 1H,
NH), 7.96-7.11 (m, 9H, 2Ar-H) and 3.32 (s, 3H, CH3 of
COCH3) ppm,
13C NMR d: 210.93, 209.44, 189.16, 172.22,
168.69, 129.31, 127.98, 114.96, 107.43, 83.07, 82.27, 55.54,
40.34, 39.79, 38.95, 32.52, 26.55, 14.66. Anal. C20H13N5O2S
(387.354): Calcd: C, 62.01; H, 3.38; N, 18.08; S, 8.26; Found:
C, 61.95; H, 3.42; N, 17.65; S, 7.99. Ms: m/z 387 M+.
2.2.5. General procedure for synthesis of 3-[1amino-2-oxo-5-
aryl-1,2-dihydropyrrol-3-Ylidene]indolin-2-ones 4a,b, 3-[1-
amino-5-oxo-2phenyl-1H imidazole 4(5H)Ylidene]indolin-2-
one 4c and 1-acetyl-3[1-amino-5-oxo-2-phenyl-1H- imidazol-
4(5H)-Ylidene]indolin-2-one (4d)
A solution of (1a–d) (0.01 mol) and hydrazinehydrate
(0.01 mol) in pyridine (50 ml) and few drops of phosphorus
oxychloride were reﬂuxed for 6 h. The solid product that sep-
arated after cooling was ﬁltered off and crystallized from ben-
zene to give (4a–d).
2.2.5.1. 3-[1-Amino-2-oxo-5-(2-methylphenyl)-1, 2-dihydropyr-
rol-3-ylidene]indolin-2-one (4a). Yellow solid, yield 56%; de-
comp. at 140 C mp165 C; IR: 3260 for (NH), 3190 for
(NH of NH2), 1674-1655 for (C‚O) cm
1 .1H NMR: d
10.43 (s, 1H, NH), 9.10 (s, 2H, NH2), 7.69-7.02 (m, 8H, 2Ar-
H), 6.40 (s, 1H, CH), 3.80 (s, 3H, CH3 of CH3-Ar) ppm, Anal.
C19H15N3O2 (317.34): Calcd: C, 71.91; H, 4.76; N, 13.24;
Found: C, 72.10; H, 4.85; N, 12.98.Ms: m/z 317 M+.
2.2.5.2. 3-[1-Amino-2-oxo-5-(2-methoxyphenyl)-1, 2-dihydro-
pyrrol-3-ylidene]indolin -2-one (4b). Brown solid, yield 53%;
decomp. at 110 C mp 160 C; IR: 3254 for (NH), 3179 for
(NH of NH2), 1670-1645 for (C‚O) cm
1 .1H NMR: d
10.22 (s, 1H, NH), 8.99 (s, 2H, NH2), 7.85-7.13 (m, 8H, 2Ar-
H), 6.67 (s, 1H, CH), 3.24 (s, 3H, CH3 of CH3O-Ar) ppm,
13C NMR d: 159.12, 127.34, 127.09, 126.49, 124.27, 121.03,
114.27, 109.09, 101.24, 55.12, 40.32, 40.09, 39.76, 39.21,
38.93, 38.65, 35.65. Anal. C19H15N3O3 (333.34): Calcd: C,
68.46; H, 4.54; N, 12.61; Found: C, 68.23; H, 4.63; N,
12.73.Ms: m/z 333 M+.
2.2.5.3. 3-[1-Amino-5-oxo-2-phenyl-1H-imidazol-4(5H)-yli-
dene]indolin -2-one (4c). Brown solid, yield 67%; decomp. at
120 C mp 140 C; IR: 3342 for (NH), 3203 for (NH of
NH2), 1670-1649 for (C‚O) and 1601 for (C‚N) cm
1. 1H
NMR d: 0.35 (s, 1H, NH), 9.25 (s, 2H, NH2) and 8.01-7.32
(m, 9H, 2Ar-H) ppm, Anal. C18H14N4O2 (318.334): Calcd:C, 67.91; H, 4.43; N, 17.60; Found: C, 67.83; H, 4.03; N,
17.63.Ms: m/z 318 M+.
2.2.5.4. 1-Acetyl-3-[1-amino-5-oxo-2-phenyl-1H-imidazol-
4(5H)-ylidene]indolin -2-one (4d). Brown solid, yield 70%;
decomp. at 100 C mp 120 C; IR: 3200 for (NH2), 1671-
1642 for (C‚O) and 1599 for (C‚N) cm1. 1H NMR: d
9.43 (s, 2H, NH2), 7.95-7.18 (m, 9H, 2Ar-H) and 2.85 (s, 3H,
CH3 of COCH3) ppm, Anal. C19H14N4O3 (346.342): Calcd:
C, 65.89; H, 4.07; N, 16.18; Found: C, 65.53; H, 4.12; N,
16.43. Ms: m/z 346 M+.
2.2.6. General procedure for synthesis of 3-[1-(-2-
methoxybenzylideneamino)-2-oxo-5-(2-methyl phenyl)-1,2-
dihydropyrrol-3-ylidene]indolin-2-one (5a) and 3-[1-(2-
methoxybenzylideneamino)-5-oxo-2-phenyl-1H-imidazol-
4(5H)-ylidene]indolin-2-one (5b)
An equimolar ratio of 4a, c (0.01 mol) and o-methoxybenzal-
dehyde in ethanol (30 ml) and few drops of piperidine were
reﬂuxed for 6 h. The reaction mixture was concentrated and
cooled. The solid that separated was ﬁltered off and crystal-
lized from ethyl alcohol to give (5a,b).
2.2.6.1. 3-[1-(2-Methoxybenzylideneamino)-2-oxo-5-(p-tolyl)-
1,2-dihydropyrrol-3-ylidene]indolin-2-one (5a). Orange solid,
yield 50%; mp 102 C; IR: 3207 for (NH), 1668-1650 for
(C‚O) cm1. 1H NMR: d 10.16 (s, 1H, NH), 8.33 (s, 1H,
CH‚N), 7.78-7.01 (m, 12H, 3Ar-H), 6.59 (s, 1H, CH), 3.85
(s, 3H, CH3 of CH3O-Ar) and 2.35 (s, 3H, CH3 of CH3-Ar)
ppm, Anal. C27H21N3O3 (435.468): Calcd: C, 74.46; H, 4.86;
N, 9.65; Found: C, 74.14; H, 4.34; 9.67.Ms: m/z 435 M+.
2.2.6.2. 3-[1-(2-Methoxybenzylideneamino)-5-oxo-2-phenyl-
1H-imidazol-4(5H) -ylidene]indolin -2- one (5b). Brown solid,
yield 45%; mp 158-60 C; IR: 3195 for (NH), 1692-1668 for
(C‚O), 1615 for (C‚N) cm1. 1H NMR: d 10.54 (s, 1H,
NH), 8.21 (s, 1H, CH‚N), 7.98-7.11 (m, 13H, 3Ar-H) and
3.67 (s, 3H, CH3 of CH3O-Ar) ppm,
13C-NMR d: 171.75,
157.57, 156.38, 141.05, 138.13, 132.92, 131.65, 131.23,
130.98, 129.43, 128.33, 127.51, 126.49, 125.10, 124.26,
121.96, 120.96, 120.62, 115.31, 112.00, 111.74, 109.97,
55.60 .Anal. C25H18N4O3 (422.434): Calcd: C, 71.08; H,
4.30; N, 13.27; Found: C, 70.86; H, 4.54; N, 13.65. Ms: m/
z 422 M+.
2.2.7. General procedure for synthesis of 3-(1-[2-(2-
methoxyphenyl)-5-oxo-2H-imidazol-1(5H)-yl)-2-oxo-5-(2-3-
(1-[2-(2methoxyphenyl)-4-oxothiazolidin-3-yl)-2-oxo-5-(2-
methyl phenyl)-1, methyl phenyl)-1,2-dihydropyrrol-3-
ylidene]indolin-2-one(6a), 3-(1-[2-(2methoxyphenyl)-5-oxo-
2H-imidazol-1(5H)-yl)-5-oxo-2-phenyl-1H-imidazol-4(5H-
ylidene] indolin-2-one (6b) and 2-dihydopyrrol-3-ylidene]
indolin-2-one (6c)
A mixture of 3-[1-(methoxybenzylideneamino)-2-oxo-5-aryl-1
and 2-dihydro-pyrrol-3-ylidene] indolin-2-ones (5a, b)
(0.01 mol) was heated above its melting point with appropriate
acetic acid derivatives (0.01 mol) in sand bath for 3 h. The
product which solidiﬁed on cooling was triturated with pet.
ether (b.p. 40–60 C), ﬁltered off and crystallized from benzene
to give (6a–c).
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1(5H)-yl)-2-oxo-5-(p-tolyl)-1,2-dihydropyrrol-3-ylidene] indo-
lin-2-one (6a). Pale brown solid, yield 47%; decomp. at
104 C; IR: 3205-3190 for (2NH) and 1661-1634 for (C‚O)
cm1. 1H NMR: d 10.52 (s, 1H, NH), 9.88 (quartet, 1H,
NH), 8.01-7.20 (m, 12H, 3Ar-H), 6.80 (s, 1H, CH), 6.73 (d,
1H, CH), 4.12 (d, 2H, CH2), 3.73 (s, 3H, CH3 of CH3O-Ar)
and 2.93 (s, 3H, CH3 of CH3-Ar) ppm, Anal. C29H24N4O4
(492.522): Calcd: C, 70.72; H, 4.91; N, 11.38; Found: C,
71.00; H, 4.62; N, 11.65. Ms: m/z 492 M+.
2.2.7.2. 3-(1-[2-(2-Methoxyphenyl)-5-oxo-2H-imidazol-
1(5H)-yl)-5-oxo-2-phenyl-1H-imidazol-4(5H)-ylidene]indolin-
2-one (6b). Pale brown solid, yield 50%; mp.230 C; IR: 3213-
3185 for (2NH), 1670-1643 for (C‚O) and 1600 for (C‚N)
cm1. 1H NMR: d 10.88 (s, 1H, NH), 9.99 (quartet, 1H,
NH), 7.98-7.05 (m, 13H, 3Ar-H), 6.78 (d, 1H, CH), 4.20 (d,
2H, CH2) and 3.70 (s, 3H, CH3 of CH3O-Ar) ppm, Anal.
C27H21N5O4 (479.488): Calcd: C, 67.63; H, 4.41.; N, 14.61;
Found: C, 67.54; H, 4.68; N, 14.65. Ms: m/z 479 M+.
2.2.7.3. 3-(1-[2-(2-Methoxyphenyl)-4-oxothiazolidin-3-yl)-2-
oxo-5-(p-tolyl)1,2-dihydropyrrol-3 ylidene] indolin-2-one (6c).
Brown solid, yield 48%; mp 90-2 C; IR: 3213 for (NH) and
1670-1660 for (C‚O) cm1. 1H NMR: d 8.94 (s, 1H, NH),
7.98-7.14 (m, 12H, 3Ar- H), 6.19-6.03 (s, 2H, 2CH), 3.90 (s,
2H, CH2), 3.18 (s, 3H, CH3 of CH3O-Ar) and 2.51 (s, 3H,
CH3 of CH3-Ar) ppm,
13C NMR d: 170.3, 168.8, 160.5,
158.4, 144.0, 142.1, 139.2, 137.6, 136.8, 131.3, 129.8, 129.0,
128.2, 126.6, 126.3, 124.3, 122.7, 121.5, 121.0, 116.6, 114.2,
100.1, 56.5, 45.6, 36.1, 24.3. Anal. C29H23N3O4S (509.504):
Calcd: C, 68.36; H, 4.55.; N, 8.25; S, 6.28, Found: C, 68.65;
H, 4.35; N, 8.65; S, 6.54. Ms: m/z 509 M+.
2.2.7. General procedure for synthesis of 3-oxo-N-[2-oxo-3-(2-
oxoindolin-3-ylidene)-5-aryl-2, 3-dihydropyrrol-1-yl]
butanamides (7a, b) and N-[4-(1-acetyl-2-oxoindolin-3-
ylidene)-5-oxo-2-phenyl-4, 5-dihydroimidazol-1-yl]-
3oxobutanamide (7c)
A solution of (4a, b, d) (0.01 mol) and ethyl acetoacetate
(0.01 mol) in ethyl alcohol (50 ml) was reﬂuxed for 3 h. The so-
lid product that separated after cooling was ﬁltered off and
crystallized from benzene to give (7a–c).
2.2.7.1. 3-Oxo-N-[2-oxo-3-(2-oxoindolin-3-ylidene)-5-(2-meth-
ylphenyl)-2,3-dihydropyrrol-1-yl] butanamide (7a). Orange so-
lid, yield 55%; mp 180 C; IR: 3267-3199 for (2NH), 1670-
1645 for (C‚O) cm1. 1H NMR: d 10.22 (s, 1H, NH), 9.99
(s, 1H, NH), 7.85- 7.13 (m, 8H, 2Ar-H), 6.67 (s, 1H, CH),
3.84 (s, 2H, CH2 of COCH2), 3.12 (s, 3H, CH3 of COCH3)
and 2.89 (s, 3H, CH3 of CH3-Ar) ppm.
13C NMR d: 176.26,
143.60, 138.80, 137.98, 132.36, 129.45, 129.39, 128.97, 127.34,
125.69, 125.55, 125.12, 124.27, 122.35, 121.04, 115.61, 109.48,
109.02, 106.75, 60.40, 29.46. Anal. C23H19N3O4 (401.412):
Calcd: C, 68.81; H, 4.77; N, 10.47; Found: C, 69.21; H, 4.42;
N, 10.76. Ms: m/z 401 M+.
2.2.7.2. 3-Oxo-N-[2-oxo-3-(2-oxoindolin-3-ylidene)-5-(2-
methoxyphenyl)-2,3-dihydropyrrol-1-yl] butanamide (7b). Pale
brown solid, yield 50%; mp 178-80 C; IR: 3325-3278 for
(2NH), 1685-1645 for (C‚O) cm1. 1H NMR: d 10.15 (s,1H, NH), 9.40 (s, 1H, NH), 7.88-7.12 (m, 8H, 2Ar-H), 6.81
(s, 1H, CH), 3.99 (s, 2H, CH2 of COCH2), 3.38 (s, 3H, CH3
of COCH3) and 3.02 (s, 3H, CH3 of CH3O-Ar) ppm, Anal.
C23H19N3O5 (417.412): Calcd: C, 66.18; H, 4.59; N, 10.07;
Found: C, 66.21; H, 4.42; N, 10.46.Ms: m/z 417 M+.
2.2.7.3. 3-N-[4-(1-Acetyl-2-oxoindolin-3-ylidene)-5-oxo-2-phe-
nyl-4,5-dihydroimidazol-1-yl]-3-oxobutanamide (7c). Brown
solid, yield 62%; mp 98-100 C; IR: 3225 for (NH), 1670-
1645 for (C‚O) and 1617 for (C‚N) cm1. 1H NMR: d
9.98 (s, 1H, NH), 7.98-7.32 (m, 9H, 2Ar-H), 3.87 (s, 2H,
CH2 of COCH2) 3.25-2.98 (s, 6H, 2CH3 of 2COCH3) ppm,
Anal. C23H18N4O5 (430.414): Calcd: C, 64.18; H, 4.22; N,
13.02; Found: C, 64.01; H, 4.34; N, 12.83. Ms: m/z 430 M+.
2.2.9. General procedure for synthesis of 3-[1-(3-
methylisoxazol-5-ylamino)-2-oxo-5-aryl-1,2-dihydropyrrol-3-
ylidene] indolin-2-ones (8a, b)
A mixture of (7a, b) (0.01 mol) and hydroxylamine hydrochlo-
ride (0.01 mol) in pyridine (30 ml) was heated under reﬂux for
2 h. The reaction mixture was evaporated under reduced pres-
sure. The solid product formed was crystallized from benzene
to give (8a,b).
2.2.9.1. 3-[1-(3-Methylisoxazol-5-ylamino)-2-oxo-5-(2-methyl
phenyl)-1,2-dihydropyrrol-3-ylidene]indolin-2-one (8a). Yellow
solid, yield 65%; mp 128-30 C; IR: 3300-3211 for (2NH),
1689-1651 for (C‚O) and 1600 for (C‚N) cm1. 1H NMR:
d 10.51 (s, 1H, NH), 9.80 (s, 1H, NH), 7.82-7.35 (m, 8H,
2ArH), 6.736.54 (s, 2H, 2CH), 3.53 (s, 3H, CH3 of CH3-Ar)
and 3.10 (s, 3H, CH3) ppm, Anal. C23H18N4O3 (398.414):
Calcd: C, 69.33; H, 4.55.; N, 14.07; Found: C, 69.21; H,
4.67; N, 13.98. Ms: m/z 398 M+.
2.2.9.2. 3-[1-(3-Methylisoxazol-5-ylamino)-2-oxo-5-(2-
methoxyphenyl)-1,2-dihydropyrrol-3- ylidene]indolin-2-one
(8b). Orange solid, yield 57%; mp 195-7 C; IR: 3400-3173
for (2NH), 1680-1651 for (C‚O) and 1607 for (C‚N)
cm1. 1H NMR: d 10.33 (s, 1H, NH), 8.99 (s, 1H, NH),
7.98-7.23 (m, 8H, 2Ar-H), 6.88-6.63 (s, 2H, 2CH), 3.72 (s,
3H, CH3 of CH3O-Ar) and 2.93 (s, 3H, CH3) ppm,
13C
NMR: d 170.3, 160.7, 160.5, 159.0, 158.9, 144.0, 142.1,
139.2, 136.8, 128.2, 127.4, 126.6, 124.3, 122.7, 121.5, 114.2,
100.2, 1001, 55.9, 17.6. Anal. C23H18N4O4 (414.414): Calcd:
C, 66.66; H, 4.38.; N, 13.52; Found: C, 67.00; H, 4.58; N,
13.45. Ms: m/z 414 M+.
2.2.10. General procedure for synthesis of 3-[1-(3-methyl-1H-
pyrazol-5-ylamino)-2-oxo-5-aryl-1,2-dihydropyrrol-3-ylidene]
indolin-2-ones (8c,d) and 1-acetyl-3-[1-(3-methyl-1H-pyrazol-
5-ylamino)-5-oxo-2-phenyl-1H-imidazol-4(5H)-ylidene]
indolin-2-one (8e)
A solution of (7a, b, d) (0.01 mol) and hydrazine hydrate
(0.01 mol) in pyridine (50 ml) and few drops of phosphorus
oxychloride were reﬂuxed for 6 h. The solid that separated
after cooling was ﬁltered off and crystallized from benzene
to give (8c–e).
2.2.10.1. 3-[1-(3-Methyl-1H-pyrazol-5-ylamino)-2-oxo-5-(2-
methyl phenyl)-1,2-dihydropyrrol-3-ylidene] indolin-2-one
(8c). Green solid, yield 50%; mp 246-8 C; IR: 3208-3180
634 H.T. Zaky et al.for (3NH), 1741-1651 for (C‚O) and 1601 for (C‚N) cm1.
1H NMR: d 10.34 (s, 1H, NH), 10.12 (s, 1H, NH), 9.49 (s, 1H,
NH), 7.73-7.01 (m, 8H, 2Ar-H), 6.40-6.23 (s, 2H, 2CH), 3.34
(s, 3H, CH3 of CH3-Ar) and 3.12 (s, 3H, CH3) ppm, Anal.
C22H18N6O3 (414.432): Calcd:C, 63.76; H, 4.38.; N, 20.28;
Found: C, 63.86; H, 4.55; N, 20.45. Ms: m/z 414 M+.
2.2.10.2. 3-[1-(3-Methyl-1H-pyrazol-5-ylamino)-2-oxo-5-(2-
methoxyphenyl)-1,2-dihydropyrrol-3-ylidene] indolin-2-one
(8d). Green solid, yield 58%; mp158 C; IR: 3310-3211 for
(3NH), 1740-1660 for (C‚O) and 1607 for (C‚N) cm1. 1H
NMR: d 10.30 (s, 1H, NH), 10.01 (s, 1H, NH), 9.33 (s, 1H,
NH), 7.87-7.21 (m, 8H, 2Ar-H), 6.65-6.32 (s, 2H, 2CH), 3.80
(s, 3H, CH3 of CH3O-Ar) and 2.52 (s, 3H, CH3) ppm, Anal.
C23H19N5O2 (397.432): Calcd: C, 69.51; H, 4.82.; N, 17.62;
Found: C, 69.71; H, 4.85; N, 17.85. Ms: m/z 397 M+.
2.2.10.3. 3-1-Acetyl-3-[1-(3-methyl-1H-pyrazol-5-ylamino)-5-
oxo-2-phenyl-1H-imidazol-4 (5H) ylidene]indolin-2-one (8e).
Green solid, yield 60%; mp 178-80 C; IR: 3201-3195 for
(2NH), 1704-1650 for (C‚O) and 1610-1601 for (C‚N)
cm1. 1H NMR: d 10.20 (s, 1H, NH), 9.40 (s, 1H, NH),
7.92-7.02 (m, 9H, 2Ar-H), 6.41 (s, 1H, CH), 3.74 (s, 3H,
COCH3) and 2.92 (s, 3H, CH3) ppm,
13C NMR d: 172.1,
166.0, 161.7, 156.5, 145.3, 144.7, 141.0, 140.3, 139.8, 130.2,
128.9, 128.7, 128.2, 126.6, 126.1, 124.3, 122.7, 121.5, 92.9,
20.2, 17.4. Anal. C23H18N6O3 (426.434): Calcd: C, 64.78; H,
4.25; N, 19.71; Found: C, 64.52; H, 4.32; N, 20.02. Ms: m/z
426 M+.
2.2.11. General procedure for synthesis of 2-chloro-N-[2-oxo-3-
(2-oxo indolin-3-ylidene)-5-(2-methoxyphenyl)-2,3-
dihydropyrrol-1-yl] acetamide (9a) and N-[4-(1-acetyl-2-
oxoindolin-3-ylidene)-5-oxo-2phenyl4,5dihydroimidazol-1-yl]-
2-chloroacetamide (9b)
A mixture of (4b, d) (0.01 mol) with chloroacetylchloride
(20 ml) was reﬂuxed for 3 h. The reaction mixture was evapo-
rated under reduced pressure. The solid product formed was
ﬁltered off and crystallized from ethyl alcohol to give the title
compounds.
2.2.11.1. 2-Chloro-N-[2-oxo-3-(2-oxoindolin-3-ylidene)-5-(2-
methoxyphenyl)-2,3-dihydro-pyrrol-1-yl] acetamide (9a).
Brown solid, yield 64%; mp 60-62 C; IR: 3201-3150 for
(2NH), 1680-1666 for (C‚O) and 1617 for (C‚N) cm1. 1H
NMR: d 10.53 (s, 1H, NH), 9.80 (s, 1H, NH), 7.99-7.21 (m,
8H, 2Ar-H), 6.95 (s, 1H, CH), 4.23 (s, 2H, CH2 of COCH2)
and 3.30 (s, 3H, CH3 of CH3O-Ar) ppm, Anal. C21H16N3O4Cl
(409.818): Calcd: C, 61.54; H, 3.94; N, 10.26; Cl, 8.65; Found:
C, 61.89; H, 4.02; N, 10.56; Cl,8.21.Ms: m/z 409 M+.2.2.11.2. 2-N-(4-[1-Acetyl-2-oxoindolin-3-ylidene)-5-oxo-2-
phenyl-4,5-dihydroimidazol-1-yl] 2-chloroacetamide (9b).
Brown solid, yield 48%; mp 90-2 C; IR: 3357-3248 for
(2NH), 1663-1635 for (C‚O) and 1601 for (C‚N) cm1. 1H
NMR: d 11.25 (s, 1H, NH), 10.52 (s, 1H, NH), 7.98-7.23 (m,
8H, 2Ar-H), 6.80 (s, 1H, CH), 4.37 (s, 2H, CH2) and 3.51 (s,
3H, CH3 of CH3O-Ar) ppm, Anal. C21H16N4O3 (372.378):
Calcd: C, 67.73; H, 4.33.; N, 15.05; Found: C, 67.87; H,
4.12; N, 14.95. Ms: m/z 372 M+.2.2.12. Synthesis of 8-(2-oxoindolin-3-ylidene)-6-(2-
methoxyphenyl) pyrrolo[1,2-b][1,2,4] triazin-3(2H,4H,8H)-
one (10)
A mixture of (9a) (0.01 mol) with ammonium acetate
(0.01 mol) in glacial acetic acid was reﬂuxed for 6 h. The solid
product that separated after cooling was ﬁltered off and crys-
tallized from benzene to give (10).
Brown solid, yield 48%; mp 90-2 C; IR: 3357-3248 for
(2NH), 1663-1635 for (C‚O) and 1601 for (C‚N) cm1. 1H
NMR: d 11.25 (s, 1H, NH), 10.52 (s, 1H, NH), 7.98-7.23 (m,
8H, 2Ar-H), 6.80 (s, 1H, CH), 4.37 (s, 2H, CH2) and 3.51 (s,
3H, CH3 of CH3O-Ar) ppm, Anal. C21H16N4O3 (372.378):
Calcd: C, 67.73; H, 4.33; N, 15.05; Found: C, 67.87; H, 4.12;
N, 14.95. Ms: m/z 372 M+.
2.2.13. General procedure for synthesis of 1-[2-oxo-3-(2-
oxoindolin-3-ylidene)-5-(2-methoxyphenyl)-2,3-dihydropyrrol-
1-yl] piperazine-2,6-dione (11a) and 4-[2-oxo-3-(2-oxoindolin-
3-ylidene)-5-(2-methoxyphenyl)-2,3-dihydropyrrol-1-yl]
thiomorpholine-3,5-dione (11b)
A solution of (9a) (0.01 mol) and glycine or thioglycolic acid
(0.01 mol) was reﬂuxed for 6 h. in pyridine (50 ml). The reac-
tion mixture after cooling was evaporated under reduced pres-
sure; the residue was poured upon cold water. The solid
product formed was ﬁltered off and crystallized from benzene
to give (11a, b).
2.2.13.1. 1-[2-Oxo-3-(2-oxoindolin-3-ylidene)-5-(2methoxy-
phenyl)-2,3-dihydropyrrol-1-yl] piperazine-2,6-dione (11a).
Brown solid, yield 60%; decomp. at 80, mp 188-90 C; IR:
3310-3270 for (2NH) and 1663 for (C‚O sharp) cm1. 1H
NMR: d 10.90 (s, 1H, NH), 10.23 (quin., 1H, NH), 7.99-7.30
(m, 8H, 2Ar-H), 5.05 (s, 1H, CH), 3.89-3.77 (d, 4H, 2CH2)
and 2.95 (s, 3H, CH3 of CH3O-Ar) ppm, Anal. C23H18N4O5
(430.414): Calcd: C, 64.18; H, 4.22; N, 13.03; Found: C,
64.47; H, 4.53; N, 12.95. Ms: m/z 430 M+.
2.2.13.2. 4-[2-Oxo-3-(2-oxoindolin-3-ylidene)-5-(2-methoxy-
phenyl)-2,3-dihydropyrrol-1-yl] thiomorpholine-3,5-dione
(11b). Brown solid, yield 48%; mp 100-2 C; IR: 3190 for
(NH) and 1670 for (C‚O sharp) cm1. 1H NMR: d 11.60
(s, 1H, NH), 8.00-7.39 (m, 8H, 2Ar-H), 5.15 (s, 1H, CH),
3.91-3.67 (s, 4H, 2CH2) and 2.51(s, 3H, CH3 of CH3O-Ar)
ppm, 13C NMR d: 170.3, 168.3, 160.5, 159.9, 144.0, 142.1,
139.2, 136.8, 128.2, 127.4, 126.6, 124.3, 122.7, 121.5, 114.2,
100.1, 55.9, 38.7 .Anal. C23H17N3O5S (447.396): Calcd: C,
61.74; H, 3.83; N, 9.39; S, 7.15; Found: C, 61.47; H, 3.59 N,
9.56; S, 7.55. Ms: m/z 447 M+.
2.3. Biological screening
The primary evaluation of in vitro cytotoxicity against human
tumor cell of the complexes under investigation has been tested
in the National Cancer Institute (NCI), Cairo University using
the method of Skehan and Storeng, 1990. The study also in-
volved the cytotoxicity evaluation of Doxorubicin as antitu-
mor agent reference as follows:
1. Cells were plated in 96-multiwell plate (105 cells/well) for
24 h before treatment with the compound to allow attach-
ment of cell to the wall of the plate.
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Scheme 1 Reagents and conditions; (i) NH2NHCSNH2/EtOH,
reﬂux; (ii) ACOH, reﬂux; (iii) NH2NHCSNH2/ACOH, reﬂux; (iv)
NH2NH2H2O/pyridine/POCl3, reﬂux.
Efﬁcient synthesis of new oxindol-based heterocyclic entities via indolin-2-one derivatives 6352. Different concentrations of the compound under test (0, 1,
2.5, 5 and 10 lg/mL) were added to the cell monolayer trip-
licate walls that were prepared for each individual dose.
3. Monolayer cells were incubated with the compound for
48 h at 37 C and in atmosphere of 5% CO2.
4. After 48 h, cells were ﬁxed, washed and stained with sulfo-
rhodamine-B stain.
5. Excess stain was washed with acetic acid and attached stain
was recovered with Tris–EDTA buffer.
6. Color intensity was measured in an ELISA reader.
7. The relation between the surviving fraction and drug con-
centration is plotted to give survival curve of cancer breast
cell line after the speciﬁed compound.
The results of the in vitro cytotoxicity activity on human tu-
mor cell line MCF7 (breast cell) were determined according to
the dose values of the drug exposure required to reduce sur-
vival in the cell lines to 50%.
3. Results and discussion
We reported early the traditional Perkin reaction of isatin with
b-aroyl propionic acids to give 1-acetyl-3-(2-oxo-5-arylfuran-
3(2H)-ylidene) indolin-2-ones (El Abbady et al., 1974), in the
present study we apply conventional Perkin reaction under
microwave reactor to give 3-(2-oxo-5-arylfuran-3(2H)-ylidene)
indolin-2-ones 1a–c. However, 3-(5-oxo-2-phenyloxazol-
4(5H)-ylidene) indolin-2-one 1d was obtained from the
reaction of hippuric acid with isatin under traditional Perkin
conditions according to the method reported in our previous
work (Kandile et al., 1991a,b). The reaction of compound 1d
with thiosemicarbazide was studied. It was noticed that the
reaction is solvent dependant. Thus conducting the reaction
of compound 1d with thiosemicarbazide in reﬂuxing absolute
ethanol for 3 h produce 1-[4-(1-acetyl-2-oxoindolin-3-yli-
dene)-5-oxo-2-phenyl-4,5-dihydroimidazol-1-yl] thiourea 2.
However, ring closure occurred on conducting the reaction
in reﬂuxing glacial acetic acid for 3 h to afford the cyclized
product 1-acetyl-3-(5-phenyl-2-thioxo-2,3-dihydro-imi-
dazo[1,5-b][1,2,4]triazol-7-ylidene) indolin-2-one 3 as illus-
trated in Scheme 1. 1H NMR spectrum of compound 2
displayed NH protons of the NH2 group which disappeared
by addition of D2O. The chemical reactivity of compounds
2a–d towards some nucleophiles such as hydrazine hydrate
was investigated. When compounds 2a–d were allowed to react
with hydrazine hydrate in reﬂuxing pyridine and few drops of
phosphorus oxychloride it afforded 3-[(1-amino-2-oxo-5-
(aryl)-1,2-dihydropyrrol-3-ylidene] indolin-2-ones (4a–d). The
structures of these compounds were established from FTIR,
1H NMR, 13C NMR, and MS spectra and elemental analysis.
The 13C NMR of 3-[1-amino-2-oxo-5-(2-methoxyphenyl)-1,2-
dihydropyrrol-3-ylidene] indolin-2-one (4b) showed bands at
159.12, 127.34, 127.09, 126.49, 124.27, 121.03, 114.27, 109.09,
101.24, 55.12, 40.32, 40.09, 39.76, 39.21, 38.93, 38.65, and
35.65. The synthetic route used to synthesize these compounds
is outlined in Scheme 1.
The structures of 3-[(1-amino-2-oxo-5-(4-aryl)-1,2-dihy-
dropyrrol-3-ylidene]indolin-2-ones (4a,c) were conﬁrmed
chemically by reaction with 2-methoxybenzaldehyde to form
the corresponding Schiff products (5a,b) named 3-[1(2-meth-
oxybenzylideneamino)-2-oxo-5-(p-tolyl)-1,2-dihydropyrrol-3-ylidene] indolin-2-one (5a) and 3-[1-(2-methoxy-benzylidenea-
mino)-5-oxo-2-phenyl-1H-imidazol-4(5H)-ylidene] indolin-2-
one (5b) as well as physically by spectral and analytical data.
1H NMR of 3-[1-(2-methoxybenzylidene-amino)-2-oxo-5-(2-
methylphenyl)-1,2-dihydropyrrol-3-ylidene] indolin-2-one
(5a) shows bands at d 10.16 (s, 1H, NH), 8.33 (s, 1H,
CH‚N), 7.78-7.01 (m, 12H, 3Ar-H), 6.59 (s, 1H, CH),
3.85 (s, 3H, CH3 of CH3O-Ar) and 2.35 (s, 3H, CH3 of
CH3-Ar) ppm. The Schiff products were utilized as key
starting materials for the synthesis of the imidazolo and
thiazolo derivatives .Attempts to cyclize the Schiff products
5a,b to the corresponding imidazolo derivatives named 3-
[1-(2-(2-methoxyphenyl)-5-oxo-2H-imidazol-1(5H)-yl)-2-oxo-
5-(p-tolyl)-1,2-dihydropyrrol-3-ylidene] indolin-2-one (6a),
and 3-[1-(2(2methoxyphenyl)-5-oxo-2H-imidazol-1(5H)-yl)-5-
oxo-2-phenyl-1H-imidazol-4(5H)-ylidene] indolin-2-one (6b)
respectively by reaction of the Schiff bases (5a,b) with gly-
cine in the presence of few drops of piperidine as a catalyst
were performed. The 1H NMR spectrum of 3-[1-(2-(2-
methoxyphenyl)-5-oxo-2H-imidazol-1(5H)-yl)-5-oxo-2-phe-
nyl-1H-imidazol-4(5H)-ylidene] indolin-2-one (6b) showed
bands at d 10.88 (s, 1H, NH), 9.99 (t, 1H, NH), 7.98-7.05
(m, 13H, 3Ar-H), 4.20 (d, 2H, CH2) and 3.70 (s, 3H, CH3
of CH3O-Ar) ppm. Also the Schiff product (5a) was cyclized
to the corresponding thiazolo derivative 3-[1-(2-(2-methoxy-
phenyl)-4-oxothiazolidin-3-yl)-2-oxo-5-(2-methyl phenyl)-1,
2-dihydopyrrol-3-ylidene] indolin-2-one (6c) by the same
636 H.T. Zaky et al.manner with thioglycolic acid. The pyrrolones (4a–c) were
treated with different electrophiles in an attempt to obtain
different heterocycles. The reaction of (4a,b,d) with ethyl
acetoacetate afforded the corresponding key products 3-
oxo-N-[2-oxo-3-(2-oxoindolin-3-ylidene)-5-aryl-2,3-dihydro-
pyrrol-1-yl]butanamide (7a,b) and N-[4-(1-acetyl-2-oxoindo-
lin-3-ylidene)-5-oxo-2-phenyl-4,5-dihydroimidazol-1-yl]-3-
oxobutanamide (7c) which show no bands for the NH2
group in IR and 1H NMR spectra. The 13C NMR of 3-
oxo-N-[2-oxo-3-(2-oxoindolin-3-ylidene)-5-(2-methyl phenyl)-
2,3-dihydropyrrol-1-yl] butanamide (7a) showed bands atN
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The oxazolo derivatives 3-[1-(3-methylisoxazol-5-ylamino)-2-
oxo-5-aryl-1,2-dihydropyrrol-3-ylidene] indolin-2-ones (8a,b)
were obtained by reaction of (7a,b) with hydroxylamine
hydrochloride in the presence of phosphorus oxychloride
.While the pyrozolo derivatives 3-[1-(3-methyl-1H-pyrazol-5-
ylamino)-2-oxo-5-aryl-1,2-dihydro-pyrrol-3-ylidene] indolin-
2-ones (8c,d) and 1-acetyl-3-[1-(3-methyl-1H-pyrazol-yl-ami-
no)-5-oxo-2-phenyl-1H-imidazol-4(5H)-ylidene] indolin-2-oneAr
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ridine, reﬂux; (ii) ZHCH2COOH, fusion; (iii) CH3COCH2COOC2-
(v) ClCH2COCl/reﬂux; (vi) CH3COONH4/glacial ACOH.
Table 1 New synthesized compounds.
Entry Compound R Ar X Z
1 1b H C6H4OCH3-o CH
2 2 COCH3 C6H5 N
3 3 COCH3 C6H5 N
4 4a H C6H4CH3-o CH
5 4b H C6H4OCH3-o H
6 4c H C6H4CH3-o N
7 4d COCH3 C6H5 N
8 5a H C6H4CH3-o CH
9 5b H C6H5 N
10 6a H C6H4CH3 CH NH
11 6b H C6H5 N NH
12 6c H C6H4CH3-o CH S
13 7a H C6H4CH3-o CH
14 7b H C6H4OCH3-o CH
15 7c COCH3 C6H5 N
16 8a H C6H4CH3-o CH O
17 8b H C6H4OCH3-o CH O
18 8c H C6H4OCH3-o N NH
19 8d H C6H4CH3-o CH NH
20 8e COCH3 C6H5 N NH
21 9a H C6H4OCH3-o CH
22 9b H C6H5 N
23 11a H C6H4OCH3-o CH NH
24 11b H C6H4OCH3-o CH S
Efﬁcient synthesis of new oxindol-based heterocyclic entities via indolin-2-one derivatives 6378e were obtained by reaction of (7a, b, d) with hydrazine hy-
drate in the presence of phosphorus oxychloride in good
yield, good analytical and spectral data. The 1H NMR of
3-[1-(3-methyl-1H-pyrazol-5-ylamino)-2-oxo-5-(2-methoxy-
phenyl)-1,2dihydropyrrol-3-ylidene] indolin-2-one (8d)
showed bands at d 10.30 (s, 1H, NH), 10.01 (s, 1H, NH),
9.33 (s, 1H, NH), 7.87-7.21 (m, 8H, 2Ar-H), 6.65-6.32Figure 2 The cytotoxicity data of the activity of compounds 6(s, 2H, 2CH),3.80 (s, 3H ,CH3 of CH3O-Ar) and 2.52 (s,
3H, CH3) ppm. The reaction of pyrrolono derivatives
(4b,d) with chloroacetylchloride yielded 2-chloro-N-[2-oxo-
3-(2-oxoindolin-3-ylidene)-5-(2-methoxyphenyl)-2,3dihydro-
pyrrol-1-yl] acetamide (9a) and N-[4-(1-acetyl-2-oxoindolin-
3-ylidene)-5-oxo-2-phenyl-4,5-dihydroimidazol-1-yl]-2-chloro-
acetamide (9b). The IR of 2 -chloro-N-[2-oxo-3-(2-oxoindo-
lin-3-ylidene)-5-(2-methoxyphenyl)-2, 3dihydropyrrol-1-yl]
acetamide (9a) showed bands at 3201-3150 for (2NH),
1680-1666 for (C‚O) and 1617 for (C‚N) cm1. 8-(2-oxo-
indolin-3-ylidene)-6-(2-methoxyphenyl) pyrrolo [1,2-
b][1,2,4]triazin-3(2H,4H,8H)-one (10) have been synthesized
via reaction of 2-chloro-N-[2-oxo-3-(2-oxoindolin-3-ylidene)-
5-(2-methoxyphenyl)-2,3dihydropyrrol-1-yl] acetamide (9a)
with ammonium acetate in glacial acetic acid. As indicated
in Scheme 2 the title compounds named 1-[2-oxo-3-(2-oxoin-
dolin-3-ylidene)-5-(4-methoxyphenyl)-2, 3-dihydropyrrol-1-yl]
piperazine-2,6-dione (11a) and 4-[2-oxo-3-(2-oxoindolin-3-yli-
dene)-5-(2-methoxy-phenyl)-2,3-dihydropyrrol-1-yl] thiomor-
pholine-3,5-dione (11b) were prepared via reaction of (9a,b)
with glycine and thioglycolic acid respectively. Further sup-
ports for the structure of these compounds were obtained
from IR, 1H NMR, and MS spectra. The synthetic route
used to synthesize these compounds is outlined in Scheme 2.
All the newly synthesized compounds are listed in Table 1.
4. In vitro cytotoxicity evaluation
Three of the newly synthesized compounds 6c, 8d and 11b were
selected as prototypes and screened against a panel human tu-
mor cell line MCF-7 (breast cancer). Primary anticancer assay
was performed in accordance with the protocol of the National
Cancer Institute, Cairo University, Egypt by the method de-
scribed in Section 2.c, 8d and 11b virus Doxorubicin (in means of IC50 values).
638 H.T. Zaky et al.The cytotoxicity data of the activity of compounds 6c, 8d
and 11b comparable with that obtained with widely used anti-
cancer drug Doxorubicin (in means of IC50 values) were re-
corded in Fig. 2. The in vitro cytotoxicity results in Fig. 2
deduced good results of these derivatives to Doxorubicin as
standard drug. The data showed that the synthesized indolin-
2-one compounds 11b and 6c showed the high activity towards
the breast tumor cell line (MCF7). But the reactivity of com-
pound 6c is more potent than the remaining compounds to-
wards the breast human cell line (MCF7).
5. Conclusion
In summary, we have reported the synthesis of novel oxindol-
based heterocyclic entities generated via the reaction of 3-[2-
oxo-5-arylfuran-3(2H)-ylidene] indolin-2-ones (1a–d) with dif-
ferent chemical reagents, then evaluation of anticancer activity
of selected compounds against human panel breast cancer cell
line MCF7. The in vitro cytotoxicity data revealed that com-
pound 6c showed the highest activity.
Declaration of interest
The authors report no conﬂict of interest. The authors alone
are responsible for the content and writing of the article.References
Alizadeh, A., Mobahedi, F., Esmaili, A., 2006. A new method for the
synthesis of fuctionalized maleimides. Tetrahedron Lett. 4, 4469.
Cariou, A.C.C., Clarkson, G.J., Shipman, M., 2008. Rapid synthesis
of 1,3,4,4-tetrasubstituted beta-lactams from methyleneaziridines
using a four-component reaction. J. Org. Chem. 73, 9762.
Chinnasamy, R.P., Panneerselvam, T., Sundararajan, R., 2012.
Indolin-2-ones in clinical trials as potential kinase inhibitors: a
review. Pharmacol. Pharm. 3, 62–71.
Cho, T.P., Dong, S.Y., Jun, F., Hong, F.J., Liang, Y.J., LuX, A., Hua,
P.J., Li, L.Y., Lei, Z., Bing, H., Ying, Z., Qiong, L.F., Bei, F.B.,
Guang, L.L., Shen, G.A., Hong, S.G., Hong, S.W., Tai, M.X., 2010.
Novel potent orally active multitargeted receptor tyrosine kinase
inhibitors: synthesis, structureactivity relationships, and antitu-
mor activities of 2-indolinone derivatives. J. Med. Chem. 53, 8140.
Chow, L.Q., Gail Eckhardt, S., 2007. Sunitinib: from rational design
to clinical efﬁcacy. J. Clin. Oncol. 25 (19), 2858.
Delgado, JN., Remers, WA., 1998. Wilson Giswold’s Book of Organic
Chemistry Medicinal and Pharmaceutical Chemistry, 10th ed.
Lippincott Raven, Philadelphia.
Demirayak, S., Kayagil, I., Yurttas, L., Aslan, R., 2011. Synthesis of
some imidazolyl thioacetylpyrazolinone derivatives and their antin-
ociceptive and anticancer activities. Eur. J.Med. Chem. 46, 411–416.
Domling, A., 2006. Recent developments in isocyanide based multicom-
ponent reactions in applied chemistry. Chem. Rev. 106 (1), 17–89.
Domling, A., UgiI, Angew, 2000. Multicomponent reactions with
isocyanides. Chem. Int. Ed. 39, 3168.
El Abbady, A.M., Omara, M.A., Kandile, N.G., 1974. Condensation
of b-aroylpropionic acids with isatin under Perkin conditions. Rev.
Roum. Chem. 19, 79–82.
Elgazwy, A.S.S., Hamad, Zaky, Howida, T., Mohamed Mansoura, I.,
Nadia G., Kandile, 2006. 2(3H)-furanones as synthons for polya-
mides of 1,3-diazines and 1,3,5-triazines. Arkivok 10, 162–172.
Hamad, A.-S.S., Kandile, N.G., Zaky, H.T., Mohamed, M.I., Ahmed,
H.M., 2003. Conversion of (3E)-furanones bearing indol nuclei into
novel amide, pyrolone and imidazol of derivatives. Heteroatom
Chem. 14, 434–442.Kandile, N.G., Abdel-Latif, T.M., El-Sayed, W.A., 1991a. Synthesis
and some reactions of 4-[N-acetyloxindolylidene]-2-aryl-5(4H)
oxazolones part (II). Rev. Roum. Chim 36 (1–3), 245.
Kandile, Nadia G., Abdel-Latif, Tahia M., El-Sayed, Wafaa A.,
1991b. Synthesis and some reactions of 4-[N-acetyloxindolylidene]-
2-Aryl-5(4H) oxazolones part (II). Rev. Roum. Chim. 36 (1-3), 245.
Kandile, N.G., Zaky, H.T., Mohamed, M.I., Ismaeel, H.M., Ahmed,
N.A., 2012. Synthesis, characterization and in vitro antimicrobial
evaluation of new compounds incorporating oxindole nucleus. J.
Enzyme Inhib. Med Chem. 27 (4), 599–608.
Nadia, Kandile G., Howida, Zaky T., Yassmin, Saleh G., Nashwa,
Ahmed A., 2013. Synthesis of a new class of antimicrobial agents
incorporating the indolin-2-one moiety. J. Enzyme Inhib. Med.
Chem. 28(4), 853–862.
Kiefer, S., Mertz, A.C., Koryakina, A., Hamburger, M., Kuenzi, P.,
2010. (E, Z)-3-(30,50-Dimethoxy-40-hydroxy-benzylidene)-2-indoli-
none blocks mast cell degranulation. Eur. J. Pharm. Sci. 40, 143.
Krug, M., Hilgeroth, A., 2008. Recent advances in the development of
multi kinase inhibitors, mini-reviews in medicinal chemistry. Mini-
Rev. Med. Chem. 8 (13), 1312–1327.
Kumar, A., Gupta, G., Serivastava, S., Bishnoi, A.K., saxena, R.,
Kant, R., Khanna, R.S., Maulik, P.A., Dwivedi, A., 2013. Novel
diastereoselective synthesis of spiropyrrolidine-oxindol derivatives
as anti-breast cancer agent. RSC Advances 3, 4731–4735.
Lackey, K., Cory, M., Davis, R., Frye, S.V., Harris, P.A., Hunter,
R.N., Jung, D.K., Mc Donald, O.B., McNutt, R.W., Peel, M.R.,
Rutkowske, R.D., Veal, J.M., Wood, E.R., 2000. The discovery of
potent cRaf1 kinase inhibitors. Bioorg. Med. Chem. Lett. 10, 223.
Lv, K., Wang, L.L., Liu, M.L., Zhou, X.B., Fan, S.Y., Liu, H.Y.,
Zheng, Z.B., Li, S., 2011. Synthesis and antitumor activity of 5-[1-
(3-(dimethylamino) propyl)-5-haloge-nated-2-oxoindolin-(3Z)-
ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxamides. Bioorg.
Med. Chem. Lett. 21, 3062–3065.
Miller, D., Remington, 1995. The Science and Practice of Pharmacy,
19th ed. MACK Publishing Company, Pennsylvania, p. 425.
Mologni, L., Rostagno, R., Brussolo, S., Knowles, P.P., Kjaer, S.,
Murray-Rust, J., Rosso, E., Zambon, A., Scapozza, L., McDonald,
N.Q., Lucchini, V., ambacorti-Passerini, C., 2010. Synthesis,
structure–activity relationship and crystallographic studies of 3-
substituted indolin-2-one RET inhibitors. Bioorg. Med. Chem. 18,
1482.
Sandrine, F., George, D., William, S., Eric, R., 2007. Molecular basis
for sunitinib efﬁcacy and future clinical development. Nat. Rev.
Drug Discovery 6 (9), 734–745.
Skehan, P., Storeng, R., 1990. New colorimetric cytotoxicity assay for
anticancer-drug screening. J. Natl. Cancer Inst. 82, 1107–1112.
Sun, L., Tran, N., Tang, F., App, H., Hirth, P., McMahon, G., Tang,
C., 1998. Synthesis and biological evaluations of 3-substituted
indolin-2-ones: a novel class of tyrosine kinase inhibitors that
exhibit selectivity toward particular receptor tyrosine kinases. J.
Med. Chem 41, 2588.
Uddin, M.I., Thirumalairajan, S., Crawfor, S.M., Cameron, T.S.,
Thompson, A.S., 2010. Improved synthetic route to C-ring ester-
functionalized prodigiosenes. Synlett 17, 2561–2564.
Umkeherer, M., Kalinski, C., Kolb, J., Burdack, C., 2006. A new and
versatile one–pot synthesis of indol-2-one by a novel Ugi-four-
component-Heck reaction. Tetrahedron Lett. 47, 2391.
Underiner, T.L., Ruggeri, B., Gingrich, D.E., 2004. Development of
vascular endothelial growth factor receptor (VEGFR) kinase
inhibitors as anti-angiogenic agents in cancer therapy. Curr. Med.
Chem. 11, 731–745.
Weber, L., 2002. Multi-component reactions and evolutionary,
Chemistry. Drug Discovery Today 7, 143–147.
Zaky, H.T., 2006. Benzoxazine, benzimidazole, imide and quinazoline
derivatives via 2(3H)-3,1 furanones. J. Bulg. Chem. Commun. 38,
248–254.
Zaky, H.T., 2007. New oxazolones as synthons for antimicrobial
compounds. J. Bulg. Chem. Commun. 39, 134–141.
